Alpha-beta T-cell receptor (TCR) (TCR)

The alpha-beta T-cell receptor (TCR) is a multi-subunit antigen-recognition complex found on the surface of the majority of T lymphocytes. It plays a pivotal role in the adaptive immune system by identifying specific peptide fragments presented by Major Histocompatibility Complex (MHC) molecules on the surface of antigen-presenting cells. In glioblastoma research, specifically using the GBM6 cell line, dendritic cells (DCs) derived from adherent monocytes (AD/DCs) are utilized to present tumor-associated antigens to TCRs to stimulate a targeted anti-tumor immune response (Prins et al., 2011, PMID: 21448148). This recognition process is the fundamental mechanism behind TCR-engineered T-cell (TCR-T) therapies and dendritic cell vaccines aimed at treating aggressive brain tumors. The TCR-pMHC interaction triggers intracellular signaling pathways, primarily through the associated CD3 complex, leading to T-cell activation, proliferation, and the release of cytotoxic granules (Janeway et al., 2001). Therapeutic targeting of the TCR aims to overcome the immune evasion strategies employed by glioblastoma, although challenges such as on-target off-tumor toxicity and cytokine release syndrome remain significant therapeutic hurdles (PubMed: 30333116).

Other names

T-cell antigen receptorTCR-CD3 complexAlpha-beta T-cell receptorGamma-delta T-cell receptorT-cell receptor alpha/beta chain

The alpha-beta T-cell receptor recognizes specific peptide antigens presented by MHC molecules on antigen-presenting cells, initiating a signaling cascade through the associated CD3 complex that leads to T-lymphocyte activation, proliferation, and effector functions such as cytokine release and target cell lysis (Janeway et al., 2001; PubMed: 25182228).